Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Not all AML treatments are created equal. A retrospective study of ~400 patients with NPM1-mutated acute myeloid leukemia found that high-intensity chemotherapy delivered a median overall survival of nearly 7 years, compared to under 2 years with lower-intensity regimens. Age, FLT3-ITD mutation, and performance status were key predictors of outcomes.
A large retrospective analysis out of MD Anderson Cancer Center is shedding new light on how treatment intensity shapes survival in NPM1-mutated (NPM1mt) acute myeloid leukemia (AML). Researchers studied 396 newly diagnosed NPM1mt AML patients treated between 2012 and 2023, finding that while overall complete remission rates exceeded 75%, survival outcomes varied dramatically depending on the regimen used.
Patients who received high-intensity chemotherapy — typically cytarabine and idarubicin combinations — fared significantly better than those on lower-intensity approaches. One promising lower-intensity option, a cladribine/low-dose cytarabine/venetoclax regimen alternating with azacitidine/venetoclax, outperformed standard hypomethylating agent plus venetoclax in age-matched comparisons.
By the Numbers
Why it matters: These findings offer clinicians concrete benchmarks for risk stratification in NPM1mt AML and highlight that treatment selection — not just mutation status — is a critical driver of long-term outcomes. Prospective studies are needed to confirm these results.
